Abstract
INTRODUCTION
Although the overall incidence of lung cancer appears to be decreasing, there is a growing public concern that the incidence in never smokers may be rising [1] . However, because of the rarity of lung cancer in never smokers and because methods of diagnosis were variable in historical patient cohorts, it is difficult to accurately estimate changes over time in true incidence rates [2] . A recent analysis of pooled cohorts and cancer registries in fact demonstrated no significant increase in the incidence of cancer in never smokers [3] . These researchers estimated the cumulative risk of never smokers dying from lung cancer as 1.1% in men and 0.8% in women.
Nevertheless, it does appear that the proportion of never smokers being treated for lung cancer is increasing. In registry data from 3 large hospital systems, the proportion of never smokers with nonsmall-cell lung cancer (NSCLC) increased from 8.0% in the years 1990-95 to 14.9% in 2011-13 [4] . Whether this proportional change is due to an actual increased incidence in never smokers versus a decrease in smoking-related lung cancer in the overall population is unknown. However, it seems likely that lung cancer physicians will increasingly treat never smokers. We therefore sought to examine the proportion of never smokers in our own surgical cohort and to determine whether these patients had distinct demographic and pathological characteristics. Importantly, we sought to determine whether smoking status independently affected survival in matched patient cohorts and to therefore determine whether lung cancer in never smokers is a more indolent disease.
PATIENTS AND METHODS

Study design and patients
We conducted a retrospective review of a prospective lung cancer database. The study was approved by the Weill Cornell Medicine, New York-Presbyterian Hospital Institutional Review Board, and patient consent was waived. The study included patients who underwent resection for NSCLC between January 1997 and July 2016. Patients without smoking history documented were excluded. Demographic, clinical, perioperative and pathological characteristics of selected patients were retrieved from the database. Patients were classified as never smokers, light-moderate smokers (<30 pack-years) or heavy smokers (> _30 pack-years).
Propensity matching was done and included the following variables: age, gender, location (upper/middle versus lower lobe), histology (adenocarcinoma versus squamous cell carcinoma vs others), pathological T stage (0/I/II vs III/IV), pathological N stage (N-ve versus N+ve) and grade (well/moderate versus poor). Propensity scores were calculated by logistic regression modelling. Matching was done one to one with the use of the nearest neighbour methods without replacement using 0.01 caliper width.
Follow-up, recurrence and survival
Follow-up was accomplished according to the established institutional standards. In brief, patients were seen in our follow-up clinic every 3 months during the 1st postoperative year, every 6 months for 2 additional years and yearly thereafter. A low-dose non-contrast computed tomography scan of the chest and upper abdomen was obtained every 6 months for 2 years and yearly thereafter. Patients from distant geographic locations were followed up by direct contact or by contacting their local physician.
Local recurrence was defined as recurrent tumour with similar histology within the same lobe. Regional recurrence was defined as recurrent tumour in the ipsilateral hilar and/or mediastinal lymph nodes. Distant recurrence was defined as evidence of tumours in another lobe within 2 years from surgery, pleural space or elsewhere outside the hemithorax.
Overall survival (OS) was defined as the time from surgery until death from any cause. Disease-free survival (DFS) was defined as the time from surgery until recurrence or death from any cause. Finally, cancer-specific survival was defined as net survival representing cancer survival in the absence of other causes of death.
Statistical analysis
Continuous variables (expressed as median, interquartile range) were compared using the Mann-Whitney U-test. Frequencies and percentages were compared for categorical variables between the 2 groups using the 2-tailed Pearson's v 2 test. Cox proportional hazards regression analysis was performed to determine the independent effects of smoking status on DFS and CSS. Univariate predictors with P-values <0.20 were included in a multivariate model. Survival probabilities were estimated using the KaplanMeier method. The log-rank test was used to determine significance of survival distributions among groups. Matched pairs were added as a random covariate in the univariate cox regression model among the matched cohort. Data analysis was performed using IBM SPSS software (version 22.0; SPSS, Inc., Chicago, IL, USA) and propensity score matching package version 3.04.
RESULTS
Clinical characteristics
Among 4140 lung cancer patients undergoing resection for lung cancer during the study period, 3232 (78.1%) had smoking status documented with the number of packs per year. From those 3232 patients, we identified 718 never smokers (22%), 993 smokers with <30 pack-year history (31%) and 1521 smokers with > _30 pack-year history (47%). The proportion, as well as the absolute number, of never smokers increased steadily over time ( Fig. 1A  and B ). In the first half of the study cohort (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) , never smokers comprised 16.1% of the cohort compared with the period after 2007 in which they comprised 26.6% of our surgical cohort. In the most recent 3 years, never smokers comprised 29.1% of patients operated on for NSCLC at our institution.
For analysis of clinical and pathological features, light-to-moderate and heavy smokers were grouped together (n = 2514). Compared to these patients, never smokers had several clinical characteristics which distinguished them (Table 1) . Never smokers were more likely to be women (76% vs 53%, P < 0.001), more likely to be identified as Asian (26.6% vs 5.4%, P < 0.001) and were younger (median age 67 vs 70, P < 0.001). Although both never smokers and smokers more often had right-sided tumours (57.2% vs 59.1%, P = 0.357), never smokers were more likely to have lower lobe tumours (38.8% vs 31.2%, P < 0.001). In patients in whom a positron emission tomography scan was performed and a maximum standardized uptake value recorded (n = 1953), tumours in never smokers were noted to be less positron emission tomography avid than tumours in smokers (maximum standardized uptake value 3.0 vs 5.0, P < 0.001). Regarding tumour histology, the majority of tumours in never smokers were adenocarcinomas (76.6%), followed by carcinoid tumours (11.4%), squamous cell tumours (4.3%) and others/not specified (7.7%). This pattern was statistically different (P < 0.001) from tumours in smokers, who although also most likely to have adenocarcinoma (70.2%), more commonly had squamous cell tumours (21.2%) and less likely had carcinoid tumours (3.7%). The study included patients who underwent induction therapy both in the never smoking cohort (n = 49, 9.2%) and in the smoking cohort (n = 273, 13.3%).
Pathological characteristics
Pathological features were relatively similar between the groups ( Table 2 ). The median pathological tumour size was 2.2 cm (interquartile range 1.5-3.3 cm) in never smokers and was 2.2 cm (interquartile range 1.5-3.5) in smokers. In never smokers, pathological T classification was pT0 in 3 patients, pT1 in 405 patients, pT2 in 236 patients and pT3/4 in 60 patients (8.4%). In smokers, pathological T classification was pT0 in 24 patients, pT1 in 52.6 patients, pT2 in 34.4 patients and pT3/4 in 299 patients (11.9%). There was no difference (P = 0.276) in the rate of nodal metastases in never smokers (20.9%) and smokers (22.9%). Final pathological stages are listed in Table 2 . Never smokers had slightly higher rates of pIA tumours, 56% vs 51.8% (P = 0.004), but fairly similar rates of other pathological stages. Never smokers were also more likely to have well/moderate differentiated tumours compared with smokers (87.7% vs 75.2%, P < 0.001), although they had similar rates of pleural and lymphovascular invasion.
Recurrence and survival
For the cohort, the median follow-up time for OS was 72.9 months [95% confidence interval (CI) 68.8-76.9]. The majority of patients were alive without recurrence in both the never smoker group (69.8%) and the smoker group (58.2%). In pathological stage-matched patients (excluding those with carcinoid tumours or those with 'other' histology), the only apparent statistical difference between the cohorts (Table 3) was an improvement in 5-year OS in pIA never smokers versus smokers (88.3% vs 78.9%, P = 0.022). Otherwise no statistically different OS or CSS rates were found between never smokers and smokers with pIA, pIB, pII or pIII/IV disease ( Fig. 2A-D) . Among patients undergoing induction therapy prior to surgery, for never smokers and smokers, 5-year OS was 50.6% vs 53.5% (P = 0.707), whereas 5-year CSS was 54.8% vs 63.2% (P = 0.828). There was an improvement in OS in the entire group according to time period, with patients To further compare the effect of smoking status in patients with similar demographic characteristics, we propensity matched 2 groups from each cohort according to several clinical and pathological variables. The groups (n = 498 each) were well balanced in terms of age, gender, tumour location and histology and pT and pN classifications (Table 4 ). In propensity-matched groups, there was no statistical difference in 5-year DFS (66% vs 67%, P = 0.661), CSS (84% vs 81%, P = 0.350, Fig. 3 ) or in freedom from recurrence (71% vs 71%, P = 0.626). On univariate analysis of the matched cohort, never smoking status had no effect on DFS (hazard ratio 1.04, 95% CI 0.83-1.30; P = 0.756) or CSS (HR 1.14, 95% CI 0.83-1.56; P = 0.437). In the propensity-matched groups, median follow-up time was 49.1 months for never smokers (95% CI 42.5-55.7 months) and 81.9 months for smokers (95% CI 71.8-92.1 months).
DISCUSSION
Although considered rare by many, lung cancer in never smokers is one of the leading causes of cancer-related mortality, accounting for an estimated 16 000 to 24 000 deaths per year [3] . This makes lung cancer in never smokers the seventh to ninth most common fatal cancer in the USA. The origin of lung cancers in never smokers is thought to be multifactorial with several possible precipitating factors including radon exposure, exposure to second-hand smoke, indoor and outdoor air pollution, occupational agents, infectious or inflammatory lung diseases or genetic factors [2] . Despite the recognition of these risk factors, an ongoing debate exists as to whether the true incidence of lung cancer in never smokers is increasing. Most large cohort studies from which conclusions have been drawn were established to evaluate cancer mortality, rather than cancer incidence. For example, 2 large American Cancer Society cohorts, the Cancer Prevention Studies I (CPS-I) and II (CPS-II), together enrolled over 2 million people from 25 states to characterize the cancerrelated risks of smoking [5] . These studies, initiated in the late 1950s and late 1980s respectively, were quite limited by the relative inability to diagnose lung cancer in the cohorts, given the lack of modern imaging and biopsy techniques. More recently, Thun et al. [3] attempted to perform a pooled analysis of several large cohort studies (representing over 630 000 and 1.8 million participants for the incidence and mortality estimates, respectively) spanning the time period between 1960 and 2004 to determine whether lung cancer incidence and mortality were increasing in never smokers. Although they found that men and certain Asian populations of never smokers had relatively higher death rates from lung cancer, they were unable to demonstrate an increased incidence of NSCLC in male or female never smokers when standardized across all ages > _40. Regardless of whether the overall incidence of lung cancer in never smokers has changed, it would appear that never smokers represent an increasing proportion of patients undergoing treatment for lung cancer. Pelosof et al. [4] recently published a retrospective review of demographic information (1990-2013) from cancer registries at 3 major institutions. They found a steady increase in never smokers being treated at each institution over time, with an overall increased percentage of never smokers from 8.0% in 1990-95 to 14.9% in 2011-13. Similarly, in a surgical patient population, Lim and colleagues [6] from the Royal Brompton & Harefield NHS Foundation Trust in London reported an increased incidence of never smokers from 13% to 28% over the 6-year period from 2008 to 2014. To our knowledge, these data have yet to be published; however, it prompted us to evaluate our own population of surgical patients to determine the proportion of never smokers. We particularly wanted to understand whether never smokers were a distinct demographic group and whether they had outcomes that were distinct from those of patients who were current or former smokers. Arguably, there is a public perception that lung cancer in never smokers may be over-diagnosed and that these cancers may at times have more of an indolent course. We sought to determine whether that is the case.
To that end, we analysed our cohort of consecutive surgical patients operated on for NSCLC between 1997 and 2016.
We identified 3232 patients in whom smoking history was clearly documented, among whom 718 were never smokers. We found that these never smokers with lung cancer have notable differences in population demographics compared with smokers. They tend to be younger, are more likely women, are more typically Asian and more commonly have an adenocarcinoma histology. These characteristics of never smokers have been previously described in broader patient cohorts [7] . In our patients, we also demonstrated that although never smokers present with similarly sized tumours, they are more likely to have lower lobe tumours that are less positron emission tomography-avid than tumours in smokers.
Given these demographic differences in our cohort and previous evidence suggesting that lung cancers in never smokers are genetically different with distinct molecular mechanisms from lung cancers in smokers [7] , we thought it is important to establish whether lung cancer in never smokers had a different biological behavior from lung cancer in smokers, as this would potentially affect survival outcomes. In that regard, we did note a slightly higher rate of Stage IA cancers in our never smoking population compared with patients who were smokers. This is perhaps surprising, as there exists a general perception that lung cancer in never smokers may present at a later stage, given delays in diagnosis. However, as our surgical cohort does not include Stage IV patients, the overall population stage distribution of never smokers cannot be estimated. It was notable, however, that the rate of nodal metastases was not different between the 2 cohorts, with nodal metastases present in 21.1% of never smokers and in 22.9% of smokers, suggesting a similar biological behaviour.
We then evaluated stage-specific survival to determine whether smoking history had any effect on long-term outcomes. In patients with Stage IA disease, not surprisingly, OS was statistically better in never smokers. These patients were unlikely to die from their lung cancers and likely developed fewer competing comorbidities than smokers. However, when analysed for cancer-specific survival, no statistical differences were apparent in any of the stage groups (IA, IB, II, III/IV) when comparing smokers versus never smokers. Results between stage groups were fairly inconsistent, which may be a reflection of the lower numbers of patients with Stage IB-III/IV disease. To further determine whether smoking status was independently associated with differences in long-term outcomes from lung cancer, we propensity matched a subgroup of patients from both the never smoker and smoker groups for several important clinical and pathological characteristics. Again in this cohort, no statistical differences existed with regard to OS, DFS or CSS, leaving us to conclude that lung cancer in never smokers have a biological behavior similar to lung cancer in smokers.
Limitations
The study is limited as a single-institution study spanning a broad time period. However, if anything the time period effect and shorter follow-up in the never smokers would actually would contribute to an underestimation of their cancer-related mortality, further supporting the idea that these are not indolent tumours. As with all studies on self-reported tobacco use, it is possible that smoking history is incorrect. Additionally, as this is a series composed only of patients undergoing surgery, we cannot comment or surmise on the overall incidence of lung cancer in never smokers or of the potential for these patients to present with metastatic disease. However, these well-annotated data from a prospectively maintained lung cancer database allowed us to gain insight into the demographics at presentation and into the survival of never smokers with lung cancer. From these data, there is no evidence in our patient cohort that lung cancers in never smokers have a more indolent course or are less likely to contribute to cancer-related mortality. Although, certainly, smokers have a higher risk of developing and dying from lung cancer, we believe it prudent to promptly seek a diagnosis in never smokers with suspected lung cancer and to treat these patients with standard-of-care local and/or systemic therapy. We would also suggest that further molecular and immunological studies should be performed on unique cohorts of tumours from never smokers to determine molecular mechanisms contributing to progression of these tumours and to determine eligibility of these patients for targeted therapies and/or immunotherapy.
